GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Elanco Animal Health Inc (NYSE:ELAN) » Definitions » ROE %

Elanco Animal Health (Elanco Animal Health) ROE % : -9.13% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Elanco Animal Health ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Elanco Animal Health's annualized net income for the quarter that ended in Dec. 2023 was $-564 Mil. Elanco Animal Health's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $6,179 Mil. Therefore, Elanco Animal Health's annualized ROE % for the quarter that ended in Dec. 2023 was -9.13%.

The historical rank and industry rank for Elanco Animal Health's ROE % or its related term are showing as below:

ELAN' s ROE % Range Over the Past 10 Years
Min: -18.22   Med: -2.63   Max: 1.33
Current: -17.82

During the past 9 years, Elanco Animal Health's highest ROE % was 1.33%. The lowest was -18.22%. And the median was -2.63%.

ELAN's ROE % is ranked worse than
76% of 1000 companies
in the Drug Manufacturers industry
Industry Median: 4.385 vs ELAN: -17.82

Elanco Animal Health ROE % Historical Data

The historical data trend for Elanco Animal Health's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elanco Animal Health ROE % Chart

Elanco Animal Health Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only 1.27 -8.19 -6.04 -1.05 -18.22

Elanco Animal Health Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.08 5.58 -5.21 -64.69 -9.13

Competitive Comparison of Elanco Animal Health's ROE %

For the Drug Manufacturers - Specialty & Generic subindustry, Elanco Animal Health's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Elanco Animal Health's ROE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Elanco Animal Health's ROE % distribution charts can be found below:

* The bar in red indicates where Elanco Animal Health's ROE % falls into.



Elanco Animal Health ROE % Calculation

Elanco Animal Health's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-1231/( (7289+6223)/ 2 )
=-1231/6756
=-18.22 %

Elanco Animal Health's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-564/( (6134+6223)/ 2 )
=-564/6178.5
=-9.13 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Elanco Animal Health  (NYSE:ELAN) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-564/6178.5
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-564 / 4140)*(4140 / 14353)*(14353 / 6178.5)
=Net Margin %*Asset Turnover*Equity Multiplier
=-13.62 %*0.2884*2.3231
=ROA %*Equity Multiplier
=-3.93 %*2.3231
=-9.13 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-564/6178.5
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-564 / -508) * (-508 / 40) * (40 / 4140) * (4140 / 14353) * (14353 / 6178.5)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.1102 * -12.7 * 0.97 % * 0.2884 * 2.3231
=-9.13 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Elanco Animal Health ROE % Related Terms

Thank you for viewing the detailed overview of Elanco Animal Health's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Elanco Animal Health (Elanco Animal Health) Business Description

Traded in Other Exchanges
Address
2500 Innovation Way, Greenfield, IN, USA, 46140
Elanco Animal Health Inc is an animal health company that is engaged in innovating, developing, manufacturing, and marketing products for companion and food animals. Geographically, the company's operations are conducted globally and sell its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
Executives
Grace Mcardle officer: EVP, MANUFACTURING AND QUALITY 2500 INNOVATION WAY, GREENFIELD IN 46140
Timothy J Bettington officer: See remarks C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
R David Hoover director C/O EDGEWELL PERSONAL CARE COMPANY, 1350 TIMBERLAKE MANOR PARKWAY, CHESTERFIELD MO 63017
Jeffrey N Simmons director, officer: Pres., Chief Executive Officer 2500 INNOVATION WAY, GREENFIELD IN 46140
John P Bilbrey director
Rajeev A. Modi officer: See Remarks 2500 INNOVATION WAY, GREENFIELD IN 46140
Paul Herendeen director C/O BAUSCH HEALTH COMPANIES INC., 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Michael J Harrington director LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Brabander Ellen De officer: See Remarks 2500 INNOVATION WAY, GREENFIELD IN 46140
Marcela A. Kirberger officer: Ex VP, Gen Counsel & Corp Sec C/O ELANCO ANIMAL HEALTH INCORPORATED, 2500 INNOVATION WAY, GREENFIELD IN 46140
Art A Garcia director 11690 N.W. 105TH STREET, MIAMI FL 33178
William F Doyle director
Uncas Gp Llc director 250 WEST 55TH STREET, 34TH FLOOR, NEW YORK NY 10019
Sachem Head Capital Management Lp director 250 WEST 55TH STREET, 34TH FLOOR, NEW YORK NY 10019
Scott D. Ferguson director 250 WEST 55TH STREET, 34TH FLOOR, NEW YORK NY 10019